BUNKA CHRISTOPHER 4/A
4/A · Lexaria Bioscience Corp. · Filed Oct 18, 2022
Insider Transaction Report
Form 4/AAmended
BUNKA CHRISTOPHER
DirectorChariman/CEO/President/CFO
Transactions
- Purchase
common shares
2022-10-13$2.10/sh+16,600$34,860→ 254,412 total(indirect: Private Holding Company) - Purchase
common shares
2022-10-12$1.99/sh+21,900$43,537→ 237,812 total(indirect: Private Holding Company)
Holdings
- 273,543
common shares
- 215,912(indirect: Private Holding Company)
common shares
Footnotes (1)
- [F1]This Form 4/A is being filed to correct the transaction code for the open market purchase of common shares made by Mr. Bunka as previously notated as a grant or award in the Form 4 originally filed on 10/13/2022.